INVESTIGADORES
POSADAS MARTINEZ Maria Lourdes
artículos
Título:
Outcomes of Incorporating IV Daratumumab for the Treatment of AL Amyloidosis in Real World Patients from a Multicenter Registry in Latin America
Autor/es:
BRULC, ERIKA B.; NATALIA SCHUTZ; MARIA LOURDES POSADAS MARTINEZ; ELSA M NUCIFORA; AGUIRRE MA; ET AL
Revista:
BLOOD, THE JOURNAL OF THE AMERICAN SOCIETY OF HEMATOLOGY - ONLINE
Editorial:
Elsevier
Referencias:
Año: 2023
ISSN:
1528-0020
Resumen:
Introduction: AL amyloidosis is characterized by the extracellular deposition of immunoglobulin light chains. Daratumumab is an anti-CD38 monoclonal antibody that has demonstrated outstanding results in the treatment of AL amyloidosis, achieving rapid and deep responses and improving OS. Nevertheless, patients with advanced cardiac disease have been usually excluded from clinical trials and data from real world patients in Latin America is lacking. Moreover, subcutaneous Daratumumab is not available in most countries in the region.Objective: To describe hematological (HR) and organ response, overall survival (OS) and event-free survival (EFS) of incorporating IV Daratumumab for the treatment of AL amyloidosis in real world patients from 5 centers in Argentina
